Palvella Therapeutics, Inc. (PVLA)

Palvella Therapeutics, Inc. is trading at $120.30, down 5.53% on the session. The 50 day average sits at $147.28 and the 200 day at $124.88, which puts the stock in a uptrend. RSI is at 36.6, which reads as weak, and MACD is bearish crossover. Volume is average.

The nearest support is around $124.49 with resistance near $156.04, so that band frames the current range. Average daily movement is roughly $7.15, or about 5.9% of the share price, which is what any stop placement has to allow for. The overall health score of 30 out of 100 combines a trend score of 33, momentum of 20 and a risk score of 40.

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.